10-K Filing

MERCK & CO., INC. CIK: 310158 FY 2020

Filing Information

Form Type	10-K
Accession Number	`0000310158-21-000004`
Period End Date	20201231
Filing Date	20210225
Fiscal Year	2020
Fiscal Period	FY
XBRL Instance	mrk-20201231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 90 Income Statement 42 Cash Flow Statement 127 Stockholders Equity 32 Comprehensive Income 21

Balance Sheet 90 line items

Line Item	Tag	Value	Unit	Period
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$86.00M	USD	Point-in-time
Allowance for doubtful accounts	`AllowanceForDoubtfulAccountsReceivableCurrent`	$85.00M	USD	Point-in-time
Inventory, Noncurrent	`InventoryNoncurrent`	$1.48B	USD	Point-in-time
Inventory, Noncurrent	`InventoryNoncurrent`	$2.20B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$9.68B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$8.06B	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.50	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	-	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	6.50B	shares	Point-in-time
Short-term investments	`MarketableSecuritiesCurrent`	$774.00M	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $85 in 2020 and $86 in 2019)	`AccountsReceivableNetCurrent`	$7.85B	USD	Point-in-time
Accounts receivable (net of allowance for doubtful accounts of $85 in 2020 and $86 in 2019)	`AccountsReceivableNetCurrent`	$6.78B	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	3.58B	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	1.05B	shares	Point-in-time
Treasury stock, shares (in shares)	`TreasuryStockShares`	1.04B	shares	Point-in-time
Inventories (excludes inventories of $2,197 in 2020 and $1,480 in 2019 classified in Other assets - see Note 7)	`InventoryNet`	$5.98B	USD	Point-in-time
Inventories (excludes inventories of $2,197 in 2020 and $1,480 in 2019 classified in Other assets - see Note 7)	`InventoryNet`	$6.31B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$5.54B	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$4.28B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$27.48B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$27.76B	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$785.00M	USD	Point-in-time
Investments	`MarketableSecuritiesNoncurrent`	$1.47B	USD	Point-in-time
Land	`Land`	$343.00M	USD	Point-in-time
Land	`Land`	$350.00M	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$11.99B	USD	Point-in-time
Buildings	`BuildingsAndImprovementsGross`	$12.64B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$15.39B	USD	Point-in-time
Machinery, equipment and office furnishings	`MachineryAndEquipmentGross`	$16.65B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$5.01B	USD	Point-in-time
Construction in progress	`ConstructionInProgressGross`	$7.32B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$32.74B	USD	Point-in-time
Property, plant and equipment (at cost)	`PropertyPlantAndEquipmentGross`	$36.97B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$18.98B	USD	Point-in-time
Less: accumulated depreciation	`AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment`	$17.69B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$13.29B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$17.99B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$15.05B	USD	Point-in-time
Goodwill	`Goodwill`	$18.25B	USD	Point-in-time
Goodwill	`Goodwill`	$19.43B	USD	Point-in-time
Goodwill	`Goodwill`	$20.24B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$14.60B	USD	Point-in-time
Other Intangibles, Net	`IntangibleAssetsNetExcludingGoodwill`	$14.20B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$6.77B	USD	Point-in-time
Other Assets	`DeferredIncomeTaxesAndOtherAssetsNoncurrent`	$10.21B	USD	Point-in-time
Total Assets	`Assets`	$84.40B	USD	Point-in-time
Total Assets	`Assets`	$91.59B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$3.61B	USD	Point-in-time
Loans payable and current portion of long-term debt	`DebtCurrent`	$6.43B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$4.59B	USD	Point-in-time
Trade accounts payable	`AccountsPayableCurrent`	$3.74B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$13.05B	USD	Point-in-time
Accrued and other current liabilities	`OtherLiabilitiesCurrent`	$12.55B	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$736.00M	USD	Point-in-time
Income taxes payable	`AccruedIncomeTaxesCurrent`	$1.57B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.67B	USD	Point-in-time
Dividends payable	`DividendsPayableCurrent`	$1.59B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$27.33B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$22.22B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$25.36B	USD	Point-in-time
Long-Term Debt	`LongTermDebtNoncurrent`	$22.74B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.01B	USD	Point-in-time
Deferred Income Taxes	`DeferredIncomeTaxLiabilitiesNet`	$1.47B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$12.48B	USD	Point-in-time
Other Noncurrent Liabilities	`OtherLiabilitiesNoncurrent`	$11.97B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019	`CommonStockValue`	$1.79B	USD	Point-in-time
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019	`CommonStockValue`	$1.79B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.59B	USD	Point-in-time
Other paid-in capital	`AdditionalPaidInCapitalCommonStock`	$39.66B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$47.36B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$46.60B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.63B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-6.19B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$82.10B	USD	Point-in-time
Stockholders' equity before deduction for treasury stock	`StockholdersEquityBeforeTreasuryStock`	$81.86B	USD	Point-in-time
Less treasury stock, at cost: 1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019	`TreasuryStockValue`	$56.79B	USD	Point-in-time
Less treasury stock, at cost: 1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019	`TreasuryStockValue`	$55.95B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$25.32B	USD	Point-in-time
Total Merck & Co., Inc. stockholders equity	`StockholdersEquity`	$25.91B	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$94.00M	USD	Point-in-time
Noncontrolling Interests	`MinorityInterest`	$87.00M	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.88B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.00B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$84.40B	USD	Point-in-time
Total Liabilities and Equity	`LiabilitiesAndStockholdersEquity`	$91.59B	USD	Point-in-time

Income Statement 42 line items

Line Item	Tag	Value	Unit	Period
Sales	`Revenues`	$47.99B	USD	Annual
Sales	`Revenues`	$46.84B	USD	Annual
Sales	`Revenues`	$42.29B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$14.11B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$13.51B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$15.48B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.10B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.62B	USD	Annual
Selling, general and administrative	`SellingGeneralAndAdministrativeExpense`	$10.47B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$13.56B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$9.87B	USD	Annual
Research and development	`ResearchAndDevelopmentExpense`	$9.75B	USD	Annual
Restructuring costs	`RestructuringCharges`	$632.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$638.00M	USD	Annual
Restructuring costs	`RestructuringCharges`	$578.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$402.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$-139.00M	USD	Annual
Other (income) expense, net	`OtherNonoperatingIncomeExpense`	$886.00M	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$33.59B	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$39.20B	USD	Annual
Total costs, expenses and other	`CostsExpensesAndOther`	$35.38B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$8.79B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$8.70B	USD	Annual
Income Before Taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$11.46B	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$2.51B	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.71B	USD	Annual
Taxes on Income	`IncomeTaxExpenseBenefit`	$1.69B	USD	Annual
Net Income	`ProfitLoss`	$6.19B	USD	Annual
Net Income	`ProfitLoss`	$9.78B	USD	Annual
Net Income	`ProfitLoss`	$7.08B	USD	Annual
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$15.00M	USD	Annual
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-27.00M	USD	Annual
Less: Net Income (Loss) Attributable to Noncontrolling Interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-66.00M	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$9.84B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$6.22B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.07B	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$3.84	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$2.79	USD	Annual
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareBasic`	$2.34	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$3.81	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$2.78	USD	Annual
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share)	`EarningsPerShareDiluted`	$2.32	USD	Annual

Cash Flow Statement 127 line items

Line Item	Tag	Value	Unit	Period
Restricted Cash	`RestrictedCash`	$258.00M	USD	Point-in-time
Restricted Cash	`RestrictedCash`	$103.00M	USD	Point-in-time
Net income	`ProfitLoss`	$6.19B	USD	Annual
Net income	`ProfitLoss`	$9.78B	USD	Annual
Net income	`ProfitLoss`	$7.08B	USD	Annual
Amortization	`AdjustmentForAmortization`	$1.90B	USD	Annual
Amortization	`AdjustmentForAmortization`	$3.10B	USD	Annual
Amortization	`AdjustmentForAmortization`	$1.97B	USD	Annual
Depreciation	`Depreciation`	$1.42B	USD	Annual
Depreciation	`Depreciation`	$1.73B	USD	Annual
Depreciation	`Depreciation`	$1.68B	USD	Annual
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$1.04B	USD	Annual
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$1.72B	USD	Annual
Intangible asset impairment charges	`GoodwillAndIntangibleAssetImpairment`	$296.00M	USD	Annual
Charge for the acquisition of VelosBio Inc.	`ChargeForAssetAcquisition`	$2.66B	USD	Annual
Charge for the acquisition of VelosBio Inc.	`ChargeForAssetAcquisition`	-	USD	Annual
Charge for the acquisition of VelosBio Inc.	`ChargeForAssetAcquisition`	-	USD	Annual
Charge for the acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	-	USD	Annual
Charge for the acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	-	USD	Annual
Charge for the acquisition of Peloton Therapeutics, Inc.	`ResearchAndDevelopmentInProcess`	$993.00M	USD	Annual
Charge for future payments related to collaboration license options	`ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions`	-	USD	Annual
Charge for future payments related to collaboration license options	`ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions`	-	USD	Annual
Charge for future payments related to collaboration license options	`ChargeForFuturePaymentsRelatedToCollaborationLicenseOptions`	$650.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-556.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-668.00M	USD	Annual
Deferred income taxes	`DeferredIncomeTaxExpenseBenefit`	$-509.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$475.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$348.00M	USD	Annual
Share-based compensation	`ShareBasedCompensation`	$417.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$49.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-184.00M	USD	Annual
Other	`OtherNoncashIncomeExpense`	$-978.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$-294.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$418.00M	USD	Annual
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$1.00B	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$911.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$508.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$855.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$724.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$230.00M	USD	Annual
Trade accounts payable	`IncreaseDecreaseInAccountsPayableTrade`	$399.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-1.14B	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$376.00M	USD	Annual
Accrued and other current liabilities	`IncreaseDecreaseInAccruedLiabilities`	$-341.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$827.00M	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$-2.36B	USD	Annual
Income taxes payable	`IncreaseDecreaseInAccruedIncomeTaxesPayable`	$560.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-266.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-453.00M	USD	Annual
Noncurrent liabilities	`IncreaseDecreaseInOtherOperatingLiabilities`	$-237.00M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$32.00M	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$2.43B	USD	Annual
Other	`IncreaseDecreaseInOtherOperatingCapitalNet`	$674.00M	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$10.92B	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$10.25B	USD	Annual
Net Cash Provided by Operating Activities	`NetCashProvidedByUsedInOperatingActivities`	$13.44B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$4.68B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$2.62B	USD	Annual
Capital expenditures	`PaymentsToAcquireProductiveAssets`	$3.47B	USD	Annual
Purchase of Seagen Inc. common stock	`PaymentsToAcquireAvailableForSaleSecuritiesEquity`	-	USD	Annual
Purchase of Seagen Inc. common stock	`PaymentsToAcquireAvailableForSaleSecuritiesEquity`	-	USD	Annual
Purchase of Seagen Inc. common stock	`PaymentsToAcquireAvailableForSaleSecuritiesEquity`	$1.00B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$95.00M	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$7.99B	USD	Annual
Purchases of securities and other investments	`PaymentsToAcquireMarketableSecurities`	$3.20B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$2.81B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$15.25B	USD	Annual
Proceeds from sales of securities and other investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$8.62B	USD	Annual
Acquisition of VelosBio Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	Annual
Acquisition of VelosBio Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	-	USD	Annual
Acquisition of VelosBio Inc., net of cash acquired	`PaymentsToAcquireBusinessThreeNetOfCashAcquired`	$2.70B	USD	Annual
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	$2.54B	USD	Annual
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisition of ArQule, Inc., net of cash acquired	`PaymentsToAcquireBusinessTwoNetOfCashAcquired`	-	USD	Annual
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	-	USD	Annual
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	-	USD	Annual
Acquisition of Antelliq Corporation, net of cash acquired	`PaymentsToAcquireBusinessFourNetOfCashAcquired`	$3.62B	USD	Annual
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	$1.04B	USD	Annual
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	Annual
Acquisition of Peloton Therapeutics, Inc., net of cash acquired	`PaymentsToAcquireBusinessFiveNetOfCashAcquired`	-	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$431.00M	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$1.36B	USD	Annual
Other acquisitions, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$294.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-130.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-378.00M	USD	Annual
Other	`PaymentsForProceedsFromOtherInvestingActivities`	$-102.00M	USD	Annual
Net Cash (Used in) Provided by Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$4.31B	USD	Annual
Net Cash (Used in) Provided by Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-9.44B	USD	Annual
Net Cash (Used in) Provided by Investing Activities	`NetCashProvidedByUsedInInvestingActivities`	$-2.63B	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$5.12B	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$-3.71B	USD	Annual
Net change in short-term borrowings	`ProceedsFromRepaymentsOfShortTermDebt`	$2.55B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$4.29B	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	-	USD	Annual
Payments on debt	`RepaymentsOfLongTermDebt`	$1.96B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	-	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.42B	USD	Annual
Proceeds from issuance of debt	`ProceedsFromIssuanceOfLongTermDebt`	$4.96B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$4.78B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$1.28B	USD	Annual
Purchases of treasury stock	`PaymentsForRepurchaseOfCommonStock`	$9.09B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.17B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$6.21B	USD	Annual
Dividends paid to stockholders	`PaymentsOfDividendsCommonStock`	$5.70B	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$591.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$361.00M	USD	Annual
Proceeds from exercise of stock options	`ProceedsFromStockOptionsExercised`	$89.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-436.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$-325.00M	USD	Annual
Other	`ProceedsFromPaymentsForOtherFinancingActivities`	$5.00M	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-2.83B	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-13.16B	USD	Annual
Net Cash Used in Financing Activities	`NetCashProvidedByUsedInFinancingActivities`	$-8.86B	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$253.00M	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$17.00M	USD	Annual
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-205.00M	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.97B	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$-1.77B	USD	Annual
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect`	$1.87B	USD	Annual
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.10B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.16B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes $258 of restricted cash at January 1, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$6.10B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$9.93B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$8.16B	USD	Point-in-time
Cash, Cash Equivalents and Restricted Cash at End of Year (includes $103 of restricted cash at December 31, 2020 included in Other Assets - see Note 6)	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$7.97B	USD	Point-in-time

Stockholders Equity 32 line items

Line Item	Tag	Value	Unit	Period
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$1.99	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.26	USD	Annual
Common stock, dividends declared (in dollars per share)	`CommonStockDividendsPerShareDeclared`	$2.48	USD	Annual
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.88B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.00B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Beginning Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$9.84B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$6.22B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.07B	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-361.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-648.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTax`	$-441.00M	USD	Annual
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)	`DividendsCommonStockCash`	$5.82B	USD	Annual
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)	`DividendsCommonStockCash`	$5.31B	USD	Annual
Cash dividends declared on common stock ($2.48 in 2020, $2.26 per share in 2019 and $1.99 per share in 2018)	`DividendsCommonStockCash`	$6.31B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$4.78B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$1.28B	USD	Annual
Treasury stock shares purchased	`TreasuryStockValueAcquiredCostMethod`	$9.09B	USD	Annual
Net income (loss) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$15.00M	USD	Annual
Net income (loss) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-27.00M	USD	Annual
Net income (loss) attributable to noncontrolling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-66.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$25.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$22.00M	USD	Annual
Distributions attributable to noncontrolling interests	`MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders`	$21.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-372.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-862.00M	USD	Annual
Share-based compensation plans and other	`StockholdersEquityOther`	$-611.00M	USD	Annual
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.88B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$26.00B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.57B	USD	Point-in-time
Ending Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$25.40B	USD	Point-in-time

Comprehensive Income 21 line items

Line Item	Tag	Value	Unit	Period
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$9.84B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$6.22B	USD	Annual
Net Income Attributable to Merck & Co., Inc.	`NetIncomeLoss`	$7.07B	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-297.00M	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$297.00M	USD	Annual
Net unrealized (loss) gain on derivatives, net of reclassifications	`OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax`	$-135.00M	USD	Annual
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$96.00M	USD	Annual
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-18.00M	USD	Annual
Net unrealized (loss) gain on investments, net of reclassifications	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$-10.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$425.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$705.00M	USD	Annual
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization	`OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax`	$279.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-223.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$153.00M	USD	Annual
Cumulative translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$96.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-361.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-441.00M	USD	Annual
Other comprehensive income (loss), net of taxes	`OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent`	$-648.00M	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$9.20B	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$5.86B	USD	Annual
Comprehensive Income Attributable to Merck & Co., Inc.	`ComprehensiveIncomeNetOfTax`	$6.63B	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.